Hu YP 2003.

Methods	Generation of allocation sequence: unstated. Blinding: not used. Sample size estimation: no information. Withdrawal/drop‐out: unstated.
Participants	Ethnic: Chinese; 157 patients (82 in herb group, M/F 45/37, mean age 50.7 years (41‐70), mean disease duration 4.5 years (0.5‐9 years). 75 in control group, M/F 39/73, mean age 51.4 years (42‐73), mean disease duration 4.2 years (0.3‐10 years)). Setting: outpatients. Inclusion criteria: type 2 diabetes diagnosed by DAD criteria (DAD 1997). Exclusion criteria: unstated.
Interventions	Experimental intervention: Sihuang capsule (mixture of more than 17 herbs), 2 capsules, orally, t.i.d, for four months; plus glibenclamide, 2.5 mg orally, t.i.d. Control intervention: glibenclamide, 2.5 mg orally, t.i.d, for four months.
Outcomes	FBG. No follow‐up was reported.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear